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ABSTRACT 
 
We examined whether blood pressure (BP) attained when using various antihypertensive 
medications differs by body mass index (BMI) and if antihypertensive medication use is 
associated with differences in other metabolic risk factors, independent of BMI. Individuals with 
hypertension from the National Health and Nutrition Examination Survey (NHANES) from 
1999-2014 were used (n=15,285) to examine the main effects and interaction between 
antihypertensive use and BMI. Generally, antihypertensive users had lower BP than those taking 
no BP medications (NoBPMed) (P<0.05), whereby in women, the differences in systolic BP 
between angiotensin-converting-enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB) 
users and NoBPMed was greater in those with obesity compared to normal weight women 
(P<0.05). Diastolic BP differences between women ARB users and NoBPMed were also greatest 
in obesity (P<0.05) whilst there were no differences in normal weight individuals (P>0.05). 
Furthermore, glucose levels, and waist circumference (in women) were higher in those using 
ACE inhibitors compared to diuretics (P<0.05). ACE inhibitors and ARBs may be more 
beneficial for BP reduction in women with obesity. However, potential cardiometabolic side 
effects of antihypertensive medications should also be considered. 
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1.0 GENERAL INTRODUCTION 
 
Obesity is becoming a global epidemic as its prevalence is increasing at an alarming rate 
around the world (1,2). Worldwide obesity has nearly tripled since 1975 and as of 2016, 
estimates show that over 650 million adults are living with obesity (3). Obesity has many 
associated cardiovascular and metabolic disorders that have become a major threat to public 
health (4). It is well established that obesity is a major risk factor for hypertension, which 
contributes to the development and progression of cardiovascular disease (CVD), the leading 
cause of mortality worldwide (3,5,6). Although lifestyle modifications are important in obesity-
associated hypertension management, most individuals with hypertension require 
antihypertensive medications to reduce blood pressure (BP) and maintain it within acceptable 
ranges (7). 
Research has shown that individuals with obesity are more likely to use antihypertensive 
medications to treat hypertension (8). With the shift of hypertension treatment towards 
pharmacological agents and the role obesity plays in the pathogenesis of hypertension (9), further 
research is necessary to examine the association between antihypertensive medication use and 
obesity on BP for this population. Given that hypertension is often accompanied with type 2 
diabetes and metabolic syndrome, antihypertensive medications may or may not exacerbate the 
health risks associated with these conditions (10). Therefore, the aim of the present thesis is to 
determine if BP attained using various antihypertensive medications differs by body mass index 
(BMI) and to determine if the use of these antihypertensive medications is associated with 
differences in glucose and lipid levels, and waist circumference, independent of BMI.  The 
findings from this study may have important clinical implications for clinicians and health care 
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professionals by providing a greater understanding on whether antihypertensive medications are 
more or less beneficial for individuals with hypertension and obesity. 
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2.0 REVIEW OF RELATED LITERATURE 
 
Introduction 
It is currently estimated that one in three US adults is living with obesity or hypertension 
(11,12). With these epidemic proportions, it is important to understand the pathways involved in 
regulating blood pressure, how antihypertensive medications act to lower blood pressure (BP), 
and how obesity alters these relationships.  
The following review will discuss hypertension, the regulation of normal blood pressure, 
obesity, health risks associated with obesity, physiological alterations that result in high blood 
pressure, and specifically how high blood pressure develops in those individuals with obesity. 
The review will also describe the current interventions available to manage and treat 
hypertension including pharmacotherapy in those with obesity. Lastly, the review will discuss 
medication dosing strategies unique for individuals with obesity.  
Hypertension 
 Hypertension is a condition in which the blood vessels have consistently raised blood 
pressure (13). Normal adults have a systolic/diastolic blood pressure (SBP/DBP) reading of 
120/80 mmHg or less and above 90/60 mmHg. When the blood pressure is greater than 140/90 
mmHg, blood pressure is considered to be within the hypertensive range (14). Most individuals 
with hypertension have no other symptoms, and therefore hypertension is considered to be a 
silent killer and significantly increases the risk of cardiovascular disease (CVD) (13). 
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Regulation of Blood Pressure 
 The regulation of blood pressure is a very complex physiologic function, dependent on 
the actions of the cardiovascular, neural, renal, and endocrine systems (15). Blood pressure may 
rise or fall depending on the physiological circumstances and metabolic demands from the body 
(16). Therefore, in investigating the pathophysiology of hypertension, a good understanding of 
the factors responsible for normal blood pressure control is needed (15,17,18).  
The blood pressure regulation system functions to correct deviations from the setpoint 
value (17). Overall, the system works using sensors that respond to blood pressure, evaluators 
that compare the existing blood pressure to the setpoint, and effector mechanisms that bring 
about changes in cardiac output (CO) and peripheral vascular resistance to reduce the difference 
between the blood pressure and setpoint (17,18).  The mechanisms used to regulate blood 
pressure depend on whether short-term or long-term adaptation is needed (18). 
Short-Term Regulation 
 One of the main mechanisms behind short-term regulation of blood pressure is the 
baroreceptor reflex mechanism (Appendix A). Baroreceptors are pressure-sensitive sensors 
located in the walls of the blood vessels and heart that respond to blood pressure changes by 
sending impulses to the brain causing changes in heart rate and smooth muscle tone (18). Under 
normal physiological conditions, the baroreceptor reflex adjusts the level of sympathetic nervous 
system (SNS) and renin-angiotensin-aldosterone system (RAAS) activation to allow 
maintenance of a constant arterial pressure by use of a negative feedback homeostatic system 
(19). When blood pressure drops too low, baroreceptor firing is reduced in order to increase 
blood pressure through vasoconstriction and increased cardiac output by increased sympathetic 
stimulation via norepinephrine (NE) release and reduced parasympathetic stimulation via 
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acetylcholine (ACh) reuptake (20). When blood pressure rises too high, baroreceptor firing is 
enhanced in order to lower blood pressure through reduced vasoconstriction and decreased 
cardiac output by decreased sympathetic stimulation via NE reuptake  and increased 
parasympathetic stimulation via ACh release (21,22). 
 
Sympathetic Nervous System (SNS)  
  The stimulated effects of the sympathetic nervous system (SNS) is achieved when 
catecholamines like epinephrine and norepinephrine bind to specific receptors known as 
adrenergic receptors (23). -adrenergic receptors are found in the heart, blood vessels, kidneys, 
and the lungs, and are responsible for regulating heart rate and blood pressure.  There are two -
adrenergic receptors responsible for blood pressure regulation, the -1 and -2 receptor. -1 
adrenergic receptors are located predominantly in the heart, while -2 adrenergic receptors are 
located in the blood vessels and other organs (24). Therefore, when bound by norepinephrine, -
1 receptors increase CO, which increases blood pressure, and when bound by epinephrine, -2 
receptors increase vascular smooth muscle relaxation; which decreases blood pressure. 
Combined, there is balanced blood pressure regulation.      
 
The Renin-Angiotensin-Aldosterone System  
RAAS is a key regulator of blood pressure and fluid balance in the body (Appendix B). 
When sodium levels in the body are low, or blood potassium is high, the kidney secretes renin. 
Renin converts angiotensinogen, which is secreted by the liver, to angiotensin I which is then 
converted to angiotensin II by the enzyme angiotensin-converting enzyme (ACE). Angiotensin II 
is a vasoconstrictor that acts on blood vessels and also promotes aldosterone secretion, both of 
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which lead to water and salt retention, and potassium excretion. Additionally, angiotensin II 
causes vasoconstriction through increased SNS activity as a secondary effect which further helps 
to restore the balance of sodium, potassium, and water (25).  
Long-Term Regulation 
 Although the neural and hormonal mechanisms which act to control blood pressure act 
rapidly, they are not effective in controlling blood pressure over days, weeks, or months (17,26). 
Instead, the brain and kidneys work together to control long-term blood pressure by regulating 
the secretion of water and sodium (18). In the situation where RAAS is inappropriately active, 
blood pressure is increased via water and sodium retention by angiotensin II  (27). When the 
body has excess extracellular fluids (increased sodium and water), the rate at which water and 
salt is excreted (diuresis and natriuresis, respectively) is increased (17). In hypertension, there is 
a chronically higher release of vasoconstrictor substances and increased renal SNS activity 
(17,18,28). Accordingly, this may shift the diuresis-natriuresis process to a higher fluid and 
blood pressure setpoint level. Therefore, many antihypertensive medications act on the diuresis-
natriuresis process by increasing sodium and water elimination to treat chronic hypertension 
(17,29). 
Obesity 
Obesity is defined as abnormal or excessive fat accumulation that presents a risk to an 
individual’s health (30). A commonly used measure in classifying overweight and obesity in the 
adult population is body mass index (BMI). BMI represents an index of an individual’s size that 
is calculated by dividing an individual’s weight in kilograms by the height in metres squared 
(kg/m2). BMI can be classified into four categories; underweight, normal weight, overweight, 
and obesity. Underweight is defined as a BMI < 18.5 kg/m2. Normal weight is defined as a BMI 
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≥ 18.5 kg/m2 and BMI < 25 kg/m2. Overweight is defined as BMI ≥ 25 kg/m2 and BMI < 30 
kg/m2. Lastly, obesity is defined as a BMI ≥ 30 kg/m2 (31). BMI provides a crude population-
level measure of overweight and obesity (30,32). 
 
Obesity Related Health Risks 
 Obesity has increased steadily over the years and has become a major public health issue 
(33,34). Worldwide, over 1.9 billion adults are overweight or are living with obesity (30). In the 
United States, more than 67% of adults are overweight or are living with obesity (35). This is of 
concern as those with obesity are at increased risk of morbidity and mortality from a number of 
chronic diseases including hypertension, type 2 diabetes, dyslipidemia, cancer, and CVD (36–38). 
 
Obesity and Hypertension 
The effects of obesity on hypertension have long been recognized (9). Studies that have 
examined the link between BMI and blood pressure have reported that a 5% weight gain is 
associated with a 20-30% increase in hypertension incidence (39). It is also estimated that at least 
60% of incident hypertension is directly associated with obesity, and the combination of obesity 
and hypertension is recognized as a leading cause of CVD risk (9,39,40).  
The etiology of hypertension differs widely amongst individuals with obesity (41). There 
is not one mechanism whereby obesity causes hypertension (42). Studies have shown that a 
variety of mechanisms involving SNS, RAAS, and diuresis-natriuresis may be altered in obesity 
(43). Therefore, a review of these changes would add to our understanding of obesity-associated 
hypertension (41,43,44). 
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SNS activity is greatly enhanced in those with concurrent obesity and hypertension (45). 
As mentioned before, in hypertension there is increased renal SNS activity, leading to over-
secretion of renin (25). Additionally, adipocytes have been shown to secrete angiotensinogen 
(46,47). Coupled together, these processes lead to upregulation of RAAS resulting in consistent 
high blood pressure. 
Angiotensin II has also been shown to play an indirect role in obesity-associated 
hypertension. Angiotensin II may influence adipocyte growth and differentiation (48,49). 
Furthermore, angiotensin II may directly stimulate leptin release from adipocytes, which can 
cause increased SNS activity (49). In severe obesity, there are chronic increases in leptin and can 
therefore have substantial effects of increased SNS activity and blood pressure (50). Elevated 
aldosterone levels are also observed in individuals with obesity-associated hypertension, 
especially in those with visceral obesity (51), however the exact mechanisms by which excess fat 
could increase aldosterone are still unknown. 
 
Management of Hypertension in Obesity 
There are many different therapies available for managing hypertension in obesity. These 
therapies can be lifestyle interventions and pharmacological therapies (52). Lifestyle 
interventions are usually recommended as the initial treatment strategy in lowering blood 
pressure which include limiting sodium intake and alcohol consumption, weight loss, and 
increasing physical activity. (53). 
 
Diet 
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Dietary modifications which are associated with effective reductions in blood pressure 
include reduced salt intake, increased potassium intake, moderation of reduced alcohol 
consumption, and consumption of a healthy diet, such as the Dietary Approaches to Stop 
Hypertension (DASH) diet (54). The DASH diet encourages individuals at risk of or with 
hypertension to eat foods that are rich in protein, fiber, potassium, magnesium, and calcium. 
These foods include fruits and vegetables, beans, nuts, whole grains, and low-fat dairy products 
(55). The combination of these foods along with limited high fat, sodium, and sugar products 
have been shown to lower blood pressure (53,56,57). The DASH diet is also a good choice for 
weight management particularly for weight reduction in those with overweight and obesity to 
reduce the risk of CVD (58). It has been suggested that every kilogram of weight reduction is 
associated with a 1 mmHg decrease in SBP and DBP (59). However, data from the National 
Health and Nutrition Examination Survey (NHANES) in the US from 1988 to 1994 and 1999 to 
2004 stated that less than 20% of adults with known hypertension were classified as accordant 
with the DASH diet (55,60,61). Therefore, while the DASH diet shows evidence as an effective 
form of hypertension treatment, there is a low adoption of the diet.  
Physical Activity  
Low physical activity is a major risk factor for hypertension (62). Therefore, physical 
activity is recommended for the prevention and treatment for hypertension (63). Exercise 
training is an important initial step that is highly efficacious in the treatment of individuals with 
mild hypertension, with or without weight loss (64). Across many studies, aerobic and resistance 
training at moderate intensity has been shown to decrease blood pressure through reductions in 
vascular resistance, with average SBP and DBP reductions of 8 mmHg and 4 mmHg, 
respectively (62,65). Additionally, acute improvements in blood pressure have been observed 
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after a single exercise session and can last up to 16 hours even with low-intensity exercise (66). 
There is a modest dose-response relationship between physical activity and blood pressure. 
Studies have observed that even 30-60 min of exercise per week is sufficient to reduce both SBP 
and DBP in hypertensive individuals (67). The magnitude of SBP reduction is also greater in 
hypertensive individuals that exercise 60-90 min per week. However, there are no greater 
reductions in blood pressure beyond 90 minutes of physical activity per week. Therefore, 
reductions in blood pressure can be achieved with minimal amounts of exercise. 
Studies suggest that physical activity programs with weight loss provide beneficial 
effects in CVD risk reduction (68). Exercise along with weight loss can have SBP reductions of 
13 mmHg and 8 mmHg for DBP (69). However, when looking at long-term adherence, about 50% 
of adults who start a physical activity program drop out within a few months (70). Thus, it may 
not be surprising that the prevalence of individuals meeting physical activity guidelines is only 
one in five USA adults (71). 
Antihypertensive Medications 
In the United States, >90% of diagnosed hypertension is treated with lifestyle 
interventions and medication use. However, to achieve optimum blood pressure goals, factors 
including access, time commitment, compliance and financial barriers may affect the delivery of 
these lifestyle interventions (70). Therefore, it may not be surprising that ~65% of patients use 
pharmacological blood pressure treatments (72). Antihypertensive pharmacotherapy has been 
demonstrated to significantly reduce the risk of death from stroke and CVD by approximately 11% 
(73). Therefore, individuals with hypertension that cannot achieve blood pressure reductions 
with lifestyle interventions are recommended to add pharmacological therapy in the treatment of 
hypertension. 
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Medications available for treatment of Hypertension 
Currently, there are five major first-line antihypertensive drug classes available; diuretics, 
ACE inhibitors, angiotensin receptor blocker (ARB), calcium channel blocker (CCB), and -
blockers that have differing underlying mechanisms (74,75). 
 
Diuretics 
 Diuretics are the most common antihypertensive medication prescribed (76,77). Also 
called “water pills,” the major role of diuretics is to reduce sodium reabsorption in the kidney 
and increase urine excretion (76,78). As mentioned previously, in hypertension the diuresis-
natriuresis curve is shifted to a high pressure level, therefore diuretics work by increasing urinary 
sodium excretion and water loss to decrease blood pressure. Currently, there are three main types 
of diuretics: loop diuretics, thiazide diuretics, and potassium-sparing diuretics. Loop and thiazide 
diuretics impair sodium reabsorption by blocking the sodium transporters in the ascending loop 
of Henle and the distal convoluted tubule, respectively (79). Potassium-sparing diuretics work in 
the collecting duct and either work as aldosterone antagonists or by inhibition of sodium 
transporters (80). Potassium-sparing diuretics are usually prescribed when potassium levels are 
low or are depleted due to other medications taken (81). Current guidelines by the National 
Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure 
recommend that for uncomplicated hypertension, thiazide-diuretics should be used, either alone 
or combined with drugs from other classes (74). 
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Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor Blockers  
 ACE inhibitors and ARBs are also first-line antihypertensive agents that have important 
roles that modify the RAAS mechanisms that control blood pressure (82). ACE inhibitors 
decrease the production of angiotensin II by inhibiting its conversion from angiotensin I, while 
ARBs decrease the effects of angiotensin II by selectively blocking the type I receptor (AT1) of 
angiotensin II (83). Therefore, both drugs act on angiotensin II activity, while ARBs may offer 
more complete angiotensin II inhibition than ACE inhibitors due to selective blockade of the 
receptor site (84). ACE inhibitors also decrease blood pressure by preventing the breakdown of 
bradykinin, resulting in vasodilation and increased blood flow to tissues (85). ARBs are 
associated with fewer side effects and higher rates of adherence as compared to ACE inhibitors 
(86). However, there is more available research on the use of ACE inhibitors in CVD risk 
reduction that may be considered before choosing ARBs over ACE inhibitors. 
-Blockers 
 -blockers are agents that play an important role in the regulation of blood pressure and 
heart function (87). -blockers are competitive antagonists that bind to beta adrenergic receptors 
(88). In the kidneys, NE binding to the receptors induces renin secretion leading to activation of 
RAAS and increased blood pressure by angiotensin II and aldosterone secretion. Therefore, -
blockers work to inhibit these pathways resulting in lower blood pressure (89). However, -
blockers can be selective or non-selective. Although there is no difference in BP lowering 
between -1-selective and nonselective -blockers (-1 and -2), nonselective beta blockers over 
time may impair renal function by reduction in glomerular filtration rate (90,91). Therefore, -1-
selective blockers may be more appropriate in the treatment of hypertension. 
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Calcium Channel Blockers  
 CCBs have been widely used to treat hypertension and are effective in reducing blood 
pressure levels along with reducing CVD risks associated with hypertension. They have good 
tolerability with few side effects (92). CCBs play a role in the inhibition of voltage-gated 
calcium channels in the vascular smooth muscle (93). CCBs decrease systemic vascular 
resistance and lower arterial blood pressure by causing vascular smooth muscle relaxation (94). 
However, at high doses, CCBs can in fact increase RAAS activity as well (95,96). Therefore, 
CCBs must be carefully prescribed and/or combined with other antihypertensive medications. 
Antihypertensive Therapy in Obesity 
  In those with obesity, antihypertensive drug therapy must be administered carefully to 
obtain optimal blood pressure and CVD risk reduction (97). In the primary care setting, 
antihypertensive therapy is considered in individuals with BMI ≥ 30 kg/m2 or with other 
comorbidities such as type 2 diabetes and dyslipidemia present. Those with obesity are reported 
to require more medications to achieve similar blood pressure values than those who are normal 
weight (98). As mentioned previously, angiotensinogen is overly expressed in obesity, therefore 
ACE inhibitors and ARBs are often used in patients with obesity (97,99–101). Additionally, 
ACE inhibitors/ARBs may have the advantage of reducing the risk of new onset diabetes, while 
-blockers and thiazide diuretics may in fact increase the risk of diabetes (100,102). Another 
point for consideration in patients with obesity is that the use of -blockers is associated with a 
10% lower metabolic rate which may lead to weight gain or impair weight loss attempts (103). 
Diuretics appear to have dose-related effects in regard to the risk of dyslipidemia and insulin 
resistance, therefore low dose diuretics are recommended if used as an adjunct (104). CCBs have 
also been proven to be as effective as ACE inhibitors or ARBs and have not been associated with 
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weight gain or adverse changes in lipids. (105). Thus, with a wide variety of antihypertensive 
medications available, it is unclear whether hypertensive individuals with obesity using these 
medications have differing blood pressures than those who are normal weight or overweight. 
 
Medication Dosing in Obesity 
While many agents are available to treat various conditions associated with obesity, 
knowledge regarding how they work in obesity is limited (106,107). In obesity, there are changes 
in hepatic metabolism and renal excretion that affect pharmacokinetics (108,109). 
Pharmacokinetic studies show that in obesity, lipophilic drugs tend to be absorbed by adipose 
tissue quickly and hydrophilic drugs that are eliminated by renal excretion have increased 
clearance from the body, which can lead to overdose or underdose situations (106,110,111). 
Therefore, in order to ensure adequate drug concentrations in those with obesity, drug treatment 
must be carefully monitored and dose testing in populations with obesity. 
 
Summary of Literature 
 It is well understood that there has been a substantial rise in hypertension and obesity. 
There is clearly a link between obesity and hypertension, and when combined, there is an even 
considerably higher risk of CVD. There has also been a rise in individuals with hypertension and 
obesity using these medications. Therefore, with the increased use of pharmacological agents to 
treat hypertension, further research is necessary to examine the association between 
antihypertensive medication use and obesity on blood pressure for this population.  
The findings from this study may have important clinical significance for health care 
professionals by providing a greater understanding on whether blood pressure attained using 
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various antihypertensive medications differ by BMI classes. These findings may also assist 
health care professionals on whether certain antihypertensive medications may be more or less 
beneficial for populations with obesity. 
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3.0 MANUSCRIPT 
 
Abstract 
Aim: We examined whether blood pressure (BP) attained when using various antihypertensive 
medications differs by body mass index (BMI) and if antihypertensive medication use is 
associated with differences in other metabolic risk factors, independent of BMI. 
Methods: Individuals with hypertension from the National Health and Nutrition Examination 
Survey (NHANES) from 1999-2014 were used (n=15,285). Linear regression analyses were used 
to examine the main effects and interaction between antihypertensive use and BMI.   
Results: Generally, antihypertensive users had lower BP than those taking no BP medications 
(NoBPMed) (P<0.05), whereby in women, the differences in systolic BP between angiotensin-
converting-enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB) users and NoBPMed 
was greater in those with obesity (ACE inhibitors: -14  1 mmHg, ARB: -16  1 mmHg) 
compared to normal weight individuals (ACE inhibitors: -9  1 mmHg, ARB: -11  1 mmHg) 
(P<0.05). Diastolic BP differences between women ARB users and NoBPMed were also greatest 
in obesity (-5  1 mmHg) (P<0.05) whilst there were no differences in normal weight individuals 
(-1  1 mmHg) (P>0.05). Furthermore, glucose levels, and waist circumference in women were 
higher in those using ACE inhibitors compared to diuretics (P<0.05).   
Conclusion: ACE inhibitors and ARBs may be more beneficial for BP reduction in women with 
obesity, with no obesity-related differences for antihypertensive medication in men. However, 
potential cardiometabolic side effects of antihypertensive medications should be considered. 
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Introduction 
Cardiovascular disease (CVD) is now recognized as the leading cause of death worldwide 
(112). In 2013, more than 50 million deaths were reported globally, and 32% of these deaths 
were attributable to CVD. Hypertension is the most quantitatively important risk factor for 
premature CVD, accounting for an estimated 54% of all strokes and 47% of all ischemic heart 
disease events globally, and is more common than other CVD risk factors such as dyslipidemia 
and type 2 diabetes (113). Obesity is a risk factor for hypertension (114,115), and over the past 
few decades, the rates of obesity have risen dramatically (116). Considering the independent and 
combined CVD risks of obesity and hypertension (117), these chronic conditions are major 
public health issues.  
The prevalence of antihypertensive medication use in US adults with hypertension has 
risen from 64% to 77% in 2001 to 2010 (72). Overall, the use of first-line antihypertensive 
medications including thiazide diuretics, -blockers, angiotensin-converting-enzyme (ACE) 
inhibitors or angiotensin receptor blockers (ARBs) has increased by 23%, 57%, 31%, and 100%, 
respectively from 2001 to 2010 (72).  However, there are many differences in the physiology of 
obesity-related hypertension that may impact the effectiveness of antihypertensive medications 
in populations with varying obesity. Moreover, body compositional differences have been 
reported to influence the pharmacokinetics of various medications (118,119). Further, 
individuals with obesity are reported to be less adherent to taking medications than lean 
individuals (120). It is also well known that medication adherence in clinical trials are far 
superior to real-world settings (121,122). Thus, with the substantial rise in antihypertensive 
medication use combined with the high obesity prevalence, it is important to examine whether 
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there are medication-related blood pressure differences by obesity status in a United States 
nationally representative sample.  
There are few studies that have directly compared blood pressure differences in 
antihypertensive users across different body mass index (BMI) categories (123–125). The 
INVEST (International Verapamil SR-Trandolapril) trial and a post-hoc analysis of the 
ACCOMPLISH (Avoiding Cardiovascular Events through Combination Therapy in Patients 
Living with Systolic Hypertension) trial in particular, found that individuals with obesity on 
calcium channel blockers (CCBs) and diuretics in combination with ACE inhibitors were at 
lower risk for experiencing a cardiovascular event than their lean counterparts (123,124). To date, 
no studies have compared blood pressure differences between different BMIs for all of the 
common first-line antihypertensive classes (122–125).  Further, past literature has only examined 
the individual blood pressure effects of the antihypertensive classes in combination (124–127), 
and thus the individual medication effects becomes difficult to assess. In addition, none of these 
studies observed the association between antihypertensive medication use on other metabolic 
risk factors. Therefore, the objective of this study will be to determine if blood pressure attained 
using various antihypertensive medications differs by BMI. This study will also determine if the 
use of antihypertensive medications is associated with differences in glucose and lipid levels, and 
waist circumference independent of BMI.  
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Methods 
Participants 
The National Health and Nutrition Examination Survey (NHANES) is a series of health 
surveys conducted by the Centers for Disease Control and Prevention (CDC) and the National 
Center for Health Statistics (NCHS). NHANES utilizes a cross-sectional, multistage, probability 
study design to select participants that are nationally representative of the civilian, non-
institutionalized U.S. population by oversampling African Americans, Mexican Americans, and 
individuals aged 60 years or older (128). The survey consists of an in-home interview, followed 
by a standardized health examination and laboratory tests in mobile examination centers (MEC). 
All participants provided their informed written consent for the in-home interview and physical 
examination, and ethics were approved by the NCHS Research Ethics Review Board. Further 
information on the study protocol and design is reported by CDC (129). 
NHANES continuous data (1999-2014) were used (n=82,091). Participants were 
excluded from analysis if they were under the age of 18 years old (n=34,735), if they had a 
BMI< 18.5 kg/m2 (n=653), and if they answered “Yes” to “Are you now taking prescribed 
medicine for high blood pressure?” but had no blood pressure medication data (n=588). 
Additionally, participants were excluded if they had missing data for BMI (n=3,246), health 
insurance status (n=347), smoking status (n=3,067), physical activity (n=5), education (n=104), 
systolic blood pressure (SBP; n=4,380), and diastolic blood pressure (DBP; n=4,611). The final 
sample size was 37,763 of which 15,285 were hypertensive (defined as self-reported doctor-
diagnosed hypertension or SBP ≥140 mmHg or DBP ≥90 mmHg or self-reported 
antihypertensive medication use) and used for analysis.  
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Any additional missing data for analysis of fasting plasma glucose (FPG), waist 
circumference (WC), triglyceride (TG), and high-density lipoprotein (HDL) was excluded (FPG: 
n=20,177; WC: n=1,061; TG: n=20,325; HDL: n=1,969). The final sample size for analysis was 
7,146 for FPG, 14,691 for WC, and 6,731 for HDL and TGs. 
 
Survey Methods 
Household Questionnaires 
 Age, sex (male/female), ethnicity (white/other), health insurance status 
(insured/uninsured), education status (< high school/ ≥ high school), physical activity 
(active/inactive) and smoking status (smoker/non-smoker) were assessed through household 
questionnaires. Participants were considered insured if they answered “Yes” to, “Are you 
covered by health insurance or some kind of health care plan? (including employment, private, 
and government health care plans).” Participants who answered “Yes” to performing moderate or 
vigorous physical activity leading to small or large increases in breathing and heart rate for at 
least 10 minutes continuously in the past 30 days were considered active. Participants that were 
current smokers were coded as smokers.  
Examination Measures 
All body measures were obtained by trained health technicians. Standing height was 
measured to the nearest tenth of a centimeter (0.1 cm) using a stadiometer with a fixed vertical 
backboard and an adjustable head piece. Weight was measured in kilograms using a digital 
weight scale. BMI was then calculated using weight in kilograms divided by height in meters 
squared (kg/m2). Participants were categorized as normal weight (18.5 kg/m2<BMI<25 kg/m2), 
overweight (25 kg/m2≤BMI<30 kg/m2), or obesity (BMI≥30 kg/m2). FPG and TG levels were 
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assessed on participants who were examined in the morning session after a minimum eight hours 
fast (NHANES 1999-2004) or nine hours fast (NHANES 2005-2014). 
Blood pressure measurements were obtained using a manual mercury 
sphygmomanometer. The blood pressure cuff was placed on the right arm unless a specific 
condition was reported prohibiting use of the right arm. Participants were seated for 5 minutes 
and were told to rest quietly before beginning blood pressure measurements. At minimum, three 
measurements were recorded with 30 seconds rest in between each measurement. If necessary, a 
fourth measurement was recorded. Blood pressure measurements were averaged and used for 
analysis.  
 
Prescription Medication Use 
 Prescription medication information was obtained through household questionnaires. 
Participants who had used prescription medication in the past 30 days were asked to provide the 
name of the medication and if possible, to provide the medication container to the examiner. 
NHANES uses a prescription medication database, Lexicon Plus®, that sorts medications by 
drug ingredients and therapeutic categories. Blood pressure medications were categorized as 
ACE inhibitors (n=4,609), -blockers (n=4,243), diuretics (n=5,054), CCBs (n=3,387), ARBs 
(n=2,279), and Other (alpha blockers, renin inhibitors, and vasodilators, n=974). Combination 
therapy was considered if participants were using ≥2 different types of antihypertensive 
medications. Monotherapy was considered if participants were using only one (1) type of 
antihypertensive medication. The no BP drug group (NoBPMed) included individuals that were 
hypertensive but not taking antihypertensive medications (n=5,443). 
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Statistical Analysis 
Descriptive characteristics were stratified by antihypertensive medication drug type. All 
analyses of antihypertensive drug types were compared to NoBPMed (hypertensive adults 
without reported antihypertensive medication use). Data was presented as means (SE) or 
prevalence, % (SE). The differences between sample characteristics were evaluated using one-
way analysis of variance (ANOVA) with Tukey’s post hoc tests for continuous variables, and 
chi-square tests for categorical variables. Linear regression analyses were used to assess the 
individual and joint associations of BMI category and antihypertensive medication use on blood 
pressure adjusted for age, sex, ethnicity, education, health insurance status, physical activity, 
smoking status, and number of antihypertensive medications. Predicted least squared mean BP 
was computed for each BMI category-antihypertensive use group. Predicted least squared means 
were computed for FPG, WC, TG, and HDL levels adjusted for age, sex, BMI, ethnicity, 
education, health insurance status, physical activity, smoking status. FPG analysis was further 
adjusted for type 2 diabetes. Differences were evaluated using Tukey’s multiple comparison tests. 
All analyses were performed using SAS version 9.4 (SAS Institute Inc., Cary, NC, USA) 
and weighted to be representative of the U.S. population. Hypothesis testing was performed at a 
significance level, α = 0.05. 
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Results 
Participant Characteristics 
 Participant characteristics are shown in Table 1. Individuals using antihypertensive 
medication were older, were more likely to have health insurance and obesity, and were less 
likely to smoke and be physically active than individuals not using antihypertensives (P < 0.05). 
Individuals taking antihypertensive medication had significantly lower systolic blood pressure 
(SBP) and diastolic blood pressure (DBP) compared to NoBPMed (P < 0.0001). Similar results 
were observed following adjustment for age, sex, BMI, ethnicity, education, smoking, physical 
activity, health insurance, and number of antihypertensive medications (data not shown). With a 
therapeutic goal of <140/90 mmHg, the blood pressure control rate for overall antihypertensive 
users was 68.4%, where individuals with obesity were more likely to have controlled blood 
pressure, compared to normal weight users (70.4% vs. 63.3%, OR, 95% CI: 1.4, 1.2-1.6). 
 
Association between BMI category and antihypertensive medication use 
 There was no interaction effect observed between BMI category and -blocker, CCB, or 
Other antihypertensive use on SBP and DBP (Figure 1, P > 0.05). However, there was a 
significant interaction between antihypertensive medication use and BMI category on DBP in 
those using diuretics (P = 0.0414). The difference in DBP between diuretic users and NoBPMed 
was slightly greater in those with obesity (-2  1 mmHg) compared to those with overweight, 
although minimal (-1  1 mmHg, P = 0.0198). Diuretic users had no significant differences in 
SBP by BMI category (P < 0.05). 
 There were significant interaction effects between ACE inhibitor or ARB use and BMI 
by sex on BP (Figure 2, ACE inhibitors SBP: P = 0.0035; ARB SBP: P = 0.0129; ARB DBP: P 
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= 0.0015). In women, the difference in SBP between ACE inhibitor users and NoBPMed was 
significantly greater in those with obesity (-14  1 mmHg, P = 0.0004) and overweight (-14  1 
mmHg, P = 0.0014) compared to normal weight (-9  1 mmHg). The difference in SBP and DBP 
between ARB users and NoBPMed was significantly greater in those with obesity (SBP: -16  1 
mmHg, P = 0.0285; DBP: -5  1 mmHg, P = 0.0269) compared to normal weight (SBP: -11  1 
mmHg, DBP: -1  1 mmHg) and overweight women (DBP: +1  1 mmHg). Conversely, there 
were no effects of ACE inhibitor or ARB use by BMI on BP in men (P > 0.05).  
After restricting analysis to individuals on only one type of antihypertensive medication, 
we observed an interaction effect between ACE inhibitor use and BMI on BP in women (SBP: P 
= 0.0059; DBP: P = 0.0014) (Table 2). The difference in SBP and DBP between ACE inhibitor 
users and NoBPMed was significantly greater in those with obesity (SBP: -15  1 mmHg, P = 
0.0021; DBP: -7  1 mmHg, P = 0.0022) compared to normal weight (SBP: -17  1 mmHg, DBP: 
-2  1 mmHg). However, in comparison to our main analysis which showed no interaction effect 
between CCB use and BMI, the restricted analysis found that the difference in SBP between 
CCB users and non-users was significantly smaller in those with obesity (-6  1 mmHg) 
compared to overweight (-11  1 mmHg, P = 0.0089) and normal weight individuals (-11  1 
mmHg, P = 0.0298). No other differences were observed. 
 
Association between antihypertensive use and other metabolic risk factors 
The association between antihypertensive medication use and FPG, TG, HDL, and WC 
levels are shown in Figure 3. Overall, there was no consistent trend observed between the use of 
all antihypertensive medications and CVD risk factors. FPG levels were significantly higher in 
those using ACE inhibitors compared to diuretics (P = 0.0125), even when analysis was 
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restricted to individuals with diabetes (P = 0.0072). Triglyceride levels were lower in ARB users 
and the Other antihypertensive medications compared to those using -blockers (ARB: P = 
0.0275; Other: P = 0.0168), although very minimal. Neither HDL levels in men and women, nor 
WC in men differed by antihypertensive medication type (P > 0.10). In women, waist 
circumference was significantly higher with ACE inhibitor use compared to diuretics, CCBs, and 
NoBPMed (diuretics: P = 0.0040; CCB: P = 0.0343; NoBPMed: P = 0.0019).   
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Discussion 
Although it is clear that all BP medications are associated with reductions in BP, to our 
knowledge, this is the first study that demonstrated ACE inhibitors and ARBs were associated 
with bigger differences in BP in women with obesity compared to lean women, while there were 
minimal differences in men and for other medication types. Nevertheless, we observed higher 
glucose, and waist circumference levels in women with ACE inhibitor use. Thus, there may be 
certain antihypertensive medications that are better suited for women with obesity as compared 
to men, which may be expected given the various mechanisms of action for antihypertensive 
medication and the known physiological differences by sex and obesity. 
The etiology of hypertension differs widely amongst individuals with obesity as a variety 
of mechanisms directly involved in blood pressure regulation including the sympathetic nervous 
system (SNS), the renin-angiotensin aldosterone system (RAAS), and fluid balance are altered 
(41,43). Thus, there may be differences in the expected effectiveness of antihypertensive 
medications in those with obesity as compared to other BMI categories (108,109). We observed 
that women with obesity had bigger differences in BP when using ACE inhibitors and ARBs 
than normal weight and overweight women which may be expected given the known physiology 
of ACE inhibitors and obesity (130–132). Estrogen has cardio-protective effects in part through 
decreasing blood pressure by downregulating ACE leading to decreased angiotensin II 
production (133–135). Conversely, obesity leads to an overexpression of angiotensinogen and 
increased blood pressure (46,47).  Thus, ACE inhibitors and ARBs may have a greater potential 
to improve hypertension for women than men, particularly in those with obesity (9,136,137). 
Furthermore, these results are consistent with the “obesity paradox” which suggests that obesity 
is associated with decreased morbidity and mortality (123,138,139). Given that hypertension is 
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one of the most important risk factors for premature CVD (113), the superior antihypertensive 
effect of medications in obesity may play a protective role in risk reduction. Indeed, the INVEST 
trial found that among patients using ACE inhibitors in combination with CCBs with a history of 
coronary heart disease and class I obesity had a 49% decreased risk of CV-related mortality, 
compared to normal-weight patients (123).  Therefore, ACE inhibitor use may contribute to the 
obesity paradox, wherein CVD morbidity and mortality is lowered in those with obesity as a 
result of superior blood pressure reduction. 
We also observed that those taking diuretics with obesity had bigger differences in blood 
pressure profiles compared to overweight, although minimal.  However, there may be a 
physiological basis for why diuretics may be preferred in obesity (124,140–142). Obesity is 
associated with increased sodium retention and is often the hallmark of hypertension in obesity 
(142,143). This is due to the lower rate of natriuresis (urinary sodium excretion) because of 
reduced natriuretic peptides (144–146). Since diuretics lower blood pressure by promoting 
natriuresis, they are a logical treatment for hypertension in those with obesity (124). The diuretic 
class also includes aldosterone antagonists and in addition to a lower rate of natriuresis, 
aldosterone levels are increased in obesity (51,147,148). Furthermore, a sub-analysis of the 
ACCOMPLISH trial found that patients with obesity taking a combination of ACE inhibitors and 
diuretics, were 39%, 60%, and 40% less likely to experience primary CVD endpoints, CVD 
deaths, and total stroke, respectively, when compared to normal weight individuals taking the 
same medications. Together this may explain in part why thiazide diuretics may offer more 
cardiovascular protection in patients with obesity than those who are of lower BMI and that they 
should be preferred for first-line therapy (124). Therefore, despite our findings, diuretics may 
still be a reasonable antihypertensive medication choice particularly for those with obesity. 
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Hypertension in individuals with obesity is commonly associated with increased 
sympathetic activity, resulting in increased cardiac output (CO) (103). CO is often regulated 
through activation of -adrenergic receptors expressed in the heart. Thus, these effects can be 
antagonized by -blockade. Some studies have shown BP is more sensitive to adrenergic 
blockade in obesity than lean individuals (149,150). However, the exact mechanisms by which 
-blockade may be more effective in obesity are not known (150). In addition, there are mixed 
findings wherein we and others observe that there are similar differences in BP with -blocker 
use across BMI (118,119). Thus, more research is needed to determine whether there are obesity 
related differences in BP attained using -blockers. 
We observed that CCBs in combination with other medications were not associated with 
BP differences by obesity status.  This finding is in line with the ACCOMPLISH sub-analysis 
that suggests that cardiovascular protection, in addition to blood pressure lowering does not 
differ by BMI in CCB users who were concurrently using ACE inhibitors (124). However, when 
we restricted the sample to those who were using CCBs alone, we observed smaller BP 
differences with CCB use in those with obesity as compared to lean which is in accordance with 
studies that have shown CCB use to be more effective in lean individuals than obesity due to the 
major hemodynamic action in reducing vascular resistance (149). In conjunction with the 
superior BP lowering effects in obesity with ACEIs that we observed, the discordant BP 
medication effects in those with obesity may have been masked in the ACCOMPLISH trial.  
However, more work in this area is needed to clarify differences in CCB effectiveness by obesity 
status. 
Our study reported higher glucose, and waist circumference levels (in women only) with 
ACE inhibitor use compared to diuretics. This is in contrast with studies that suggest ACE 
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inhibitors have beneficial effects on glucose metabolism, lipid profiles and insulin sensitivity, 
making them particularly attractive for first-line therapy (151,152). ACE inhibitors have been 
shown to improve glucose metabolism via translocation of the glucose transporters to the cell 
surface which increases glucose uptake (153–155). However, our results demonstrate elevated 
glucose levels with ACE inhibitor use compared to diuretics. This difference may be explained 
in part by the higher ACE inhibitor use, but lower use of diuretics in individuals with diabetes as 
these differences remained even when the analysis was restricted to individuals with diabetes.  
Alternatively, there could be an unknown interaction between the different medications. In 
addition to higher glucose, we also observed higher waist circumference levels in women with 
ACE inhibitor use compared to diuretics. Diuretics promote diuresis which can lead to weight 
loss with increases in dose (156). Furthermore, a study by Patil et al. (157) also found that 
individuals that were administered ACE inhibitors, had an increased waist-hip ratio after 6 
months, but did not provide a mechanism behind this observation nor did they examine 
metabolic differences (157). Therefore, ACE inhibitor use may be associated with differential 
changes in metabolic risk factors, independent of BMI, but more work is needed to clarify the 
effects of ACE inhibitors alone and in combination with other medications.  
This study had strengths and limitations. The use of NHANES data allows for a large 
analytic sample that is nationally representative of the US population (129). Additionally, 
prescription medication, examination, and blood pressure data were collected through personal 
interviews and questionnaires which have been shown to reduce nonresponse when both data 
collection modes are used (158). Another strength was the adjustment of many confounding 
variables associated with blood pressure and medication use. A key limitation in this study 
includes using cross-sectional survey data which cannot determine causality. Although the blood 
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pressure medications included in the sample are first-line antihypertensive medications, they are 
also prescribed to treat other conditions (159) and the specific reason for prescription could not 
be determined nor could adherence. Furthermore, we were not able to account for dose-related 
effects; however, we did adjust for the number of antihypertensive medications taken. Overall, 
this study was weighted to be nationally representative of the US population which demonstrated 
that certain antihypertensive medications may have clinical impacts on blood pressure and other 
metabolic risk factors in those with and without obesity.  
In conclusion, our study suggested that ACE inhibitors and ARBs may be associated with 
a greater BP reduction in women with obesity compared to normal weight women, with no 
differences in BP between antihypertensive medication use by obesity in men. However, we did 
observe elevated glucose, and WC levels (in women) with ACE inhibitor use. Therefore, obesity 
status, in addition to potential side effects of antihypertensive medications on cardiometabolic 
risk should be considered. Future studies should therefore examine the long-term effectiveness of 
antihypertensive medications on blood pressure, other cardiometabolic risk factors, and 
morbidity and mortality risk to determine the most appropriate choice of treatment for those with 
and without obesity. 
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4.0 GENERAL DISCUSSION 
 
Obesity is a growing global health concern (160). This growing obesity epidemic is a 
major source of morbidity and mortality because of its association with hypertension, type 2 
diabetes, dyslipidemia, certain cancers and major cardiovascular diseases (160). In particular, the 
effects of obesity on hypertension have long been recognized (9). It is estimated that at least 60% 
of incident hypertension is directly associated with obesity, and the combination of obesity and 
hypertension is recognized as a leading cause of CVD risk (9,39,40). 
Obesity and related chronic conditions have been associated with increased costs of 
medical services and have also been linked to higher prescription drug utilization (161). In 
addition, research has shown that geographical areas with more primary care physicians are 20% 
less likely to be living with obesity than those living in areas with a shortage of physicians (162). 
Further, the lack of universal health care in the United States may prevent individuals with 
obesity to seek medical treatment as they perceive multiple barriers to treatments (163). When 
coupled with hypertension that manifests with little to no warning signs, diagnosis becomes 
difficult if blood pressure is not monitored regularly (164). Thus, access to health care for this 
population improves the diagnosis, treatment, and management of hypertension and many other 
chronic conditions.  
While lifestyle interventions are usually recommended as the initial treatment strategy in 
lowering blood pressure, optimal blood pressure goals are often not achieved, and 
pharmacological treatment is needed (9). Antihypertensive therapy has been demonstrated to 
significantly reduce the risk of death from stroke and CVD by approximately 11%, providing 
benefits beyond blood pressure lowering (73). Approximately 65% of hypertensive patients use 
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pharmacological blood pressure treatments (72). Although there are guidelines for the treatment 
of hypertension for individuals with cardiovascular diseases and type 2 diabetes (75), these 
guidelines fail to provide recommendations on the management of hypertension using 
medications in those with obesity (165).     
Studies have shown that obesity alters a variety of mechanisms that are involved in blood 
pressure regulation including SNS, RAAS, and diuresis-natriuresis (43). This thesis demonstrates 
that antihypertensive medications that act on RAAS may be more advantageous for individuals 
with obesity, particularly in women. Thus, these findings may add to studies akin to Cataldi et al., 
that suggest there is no certain antihypertensive medication used as a first choice in the treatment 
of hypertension for individuals with obesity (166). Moreover, these findings may assist policy 
makers in establishing guidelines on the management of hypertension for individuals with 
obesity. 
Differences in the treatment and control of blood pressure between men and women have 
been noted by many studies (167,168). Premenopausal women have been shown to have a lower 
risk of hypertension compared to men, but this advantage seems to disappear after menopause 
(167). After 65 years of age, women are more likely to have hypertension than men, and in 
women between the ages of 65 and 74, the prevalence of hypertension is as high as 58%. In 
addition, renin activity increases after menopause in women, suggesting antihypertensive therapy 
targeting RAAS to be more beneficial in BP reduction (169). However, BP control rates in 
women treated for hypertension still remain lower than men (170). Despite our findings that 
suggest ACE inhibitors and ARBs may have the greater potential to improve hypertension in 
women than men, women still exhibit a steeper increase in the risk of a cardiovascular event with 
increases in BP than men (171). Further, more women than men suffer recurrent strokes within 5 
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years after their first stroke, with prevalence rates up to 11% higher in women (172). A higher 
prevalence of stroke may also exist among middle-aged women compared with men, which may 
be attributed to the growing rates of obesity and metabolic syndrome in middle-aged women 
(172). Thus, there is a greater need for hypertension awareness, treatment, and management in 
women than men. 
 In conclusion, this thesis demonstrates that ACE inhibitors and ARBs may be associated 
with a greater BP reduction in women with obesity compared to normal weight women, 
suggesting certain antihypertensive medications may be better suited in individuals with obesity. 
However, we did observe higher glucose, and WC levels (in women) with ACE inhibitor use as 
compared to diuretics. Clinically, this may suggest that ACE inhibitors or ARBs may be 
considered to treat hypertension in obesity. However, when prescribing antihypertensive 
medications, further consideration should be given to the metabolic risk profile of individual 
patients.  
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Table 1. Descriptive characteristics of US adults with hypertension by antihypertensive medication type (NHANES 1999-2014). 
Continuous data presented as means (SE), categorical data presented as prevalence, % (SE), estimates weighted to represent the US population. Antihypertensive 
drug groups are not mutually exclusive. * = Significantly different from no antihypertensive drug group (P < 0.05). 
ACE=angiotensin-converting enzyme; CCB=calcium channel blocker; ARB=angiotensin receptor blocker; BP=blood pressure; HS=high school; BMI=body 
mass index; Normal weight=18.5 kg/m2<BMI<25 kg/m2; Overweight=25 kg/m2≤BMI<30 kg/m2; Obesity=BMI≥30 kg/m2; SE=standard error. 
 
No BP 
Drug 
ACE 
Inhibitors 
β-blockers Diuretics CCB ARB Other 
Participant 
Characteristics 
(n=5443)  (n=4609)   (n=4243)  (n=5054)  (n=3387)  (n=2279)  (n=974)  
Age, years 49.0 (0.3) 61.0 (0.3)* 63.3 (0.3)* 62.4 (0.3)* 63.6 (0.3)* 62.5 (0.4)* 66.8 (0.5)* 
Sex (Female) 45.3 (0.8) 48.0 (0.9)* 53.5 (1.0)* 62.8 (0.8)* 53.4 (1.1)* 57.4 (1.3)* 28.4 (1.9)* 
Ethnicity (White) 69.0 (1.5) 74.6 (1.3)* 79.3 (1.1)* 74.9 (1.3)* 68.9 (1.6) 74.4 (1.6) 73.5 (1.9)* 
Education (HS or more) 79.7 (0.8) 77.3 (1.0)* 78.0 (1.0) 76.1 (0.9) 74.8 (1.0)* 80.7 (1.0)* 71.6 (2.2)* 
Health Insurance (Insured) 78.8 (0.8) 92.6 (0.5)* 93.8 (0.4)* 93.6 (0.6)* 94.2 (0.5)* 95.0 (0.6)* 94.7 (0.9)* 
Smoking Status (Smoker) 25.3 (0.9) 16.0 (0.7)* 15.2 (0.8)* 12.8 (0.7)* 14.4 (0.9)* 10.4 (0.9)* 12.6 (1.5)* 
Physical Activity Status 
(Active) 
55.2 (1.0) 46.2 (1.1)* 45.9 (1.1)* 43.9 (1.3)* 45.0 (1.0)* 47.5 (1.7)* 45.3 (2.2)* 
Body Mass Index (BMI)         
Normal Weight 24.3 (0.7) 16.0 (0.6)* 18.5  (0.7)* 14.5 (0.6)* 18.5 (0.8)* 14.1 (0.9)* 15.8 (1.4)* 
Overweight  35.4 (0.8) 33.6 (0.9) 34.9 (0.9) 30.6 (0.9)* 32.6 (0.9)* 31.7 (1.4)* 33.5 (1.7) 
Obesity  40.3 (0.9) 50.4 (0.9)* 46.6 (0.9)* 54.9 (1.0)* 48.9 (1.0)* 54.2 (1.4)* 50.7 (1.8)* 
Blood Pressure (mmHg)        
Systolic 138 (1) 130 (1)* 132 (1)* 131 (1)* 135 (1)* 133 (1)* 133 (1)* 
Diastolic 79 (1) 70 (1)* 70 (1)* 70 (1)* 69 (1)* 70 (1)* 68 (1)* 
% control 39.8 (1.1) 70.6 (0.9)* 66.7 (0.9)* 68.7 (0.8)* 62.5 (1.1)* 65.9 (1.2)* 66.0 (1.8)* 
Number of BP Meds -------- 2.0 (0.1) 2.3 (0.1) 2.4 (0.1) 2.4 (0.1) 2.3 (0.1) 2.8 (0.1) 
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Figure 1. Mean systolic and diastolic blood pressures (mmHg) among hypertensive adults using 
A) -blockers, B) Diuretics, C) CCBs and D) Other antihypertensive drugs by BMI category. 
Sample includes individuals on combination antihypertensive therapy. Means are adjusted for 
age, sex, ethnicity, health insurance status, smoking status, physical activity, education, and 
number of antihypertensive medications taken. BMI=body mass index; BB=beta blocker; 
DIUR=diuretic; CCB=calcium channel blocker; NW=normal weight; OW=overweight; 
OB=obesity; SBP=systolic blood pressure; DBP=diastolic blood pressure. 
† = difference between users and non-users significantly different from overweight (p<0.05). 
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Figure 2. Mean blood pressures (mmHg) among hypertensive adults using A) ACE Inhibitors 
and B) ARBs by BMI category and sex. Sample includes individuals on combination 
antihypertensive therapy. Means are adjusted for age, ethnicity, health insurance status, smoking 
status, physical activity, education, and number of antihypertensive medications taken. 
BMI=body mass index; ACE=ACE Inhibitor; ARB=angiotensin receptor blocker; NW=normal 
weight; OW=overweight; OB=obesity; BP=blood pressure; SBP=systolic blood pressure; 
DBP=diastolic blood pressure. 
* = difference between users and non-users significantly different from normal weight (p<0.05), 
† = difference between users and non-users significantly different from overweight (p<0.05).  
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Table 2. Blood pressure differences between users and non-users of individuals on antihypertensive monotherapy by BMI category. 
 
Data presented as mean difference (SE), estimates weighted to represent the US population. Means are adjusted for age, sex, ethnicity, 
health insurance status, smoking status, physical activity, and education. 
ACE=angiotensin-converting enzyme; CCB=calcium channel blocker; ARB=angiotensin receptor blocker; SBP=blood pressure; 
DBP=diastolic blood pressure; BMI=body mass index; Normal weight=18.5 kg/m2<BMI<25 kg/m2; Overweight=25 kg/m2≤BMI<30 
kg/m2; Obesity=BMI≥30 kg/m2; SE=standard error; M=Men; W=Women.  
* = significantly different from normal weight (p<0.05), † = significantly different from overweight (p<0.05).  
 
 
 
Normal Weight Overweight Obesity 
N (%) 
BP Diff 
(mmHg) 
N (%) 
BP Diff 
(mmHg) 
N (%) 
BP Diff 
(mmHg) 
SBP (mmHg)       
ACE Inhibitors 305 (17.8) 
M: -16 (1) 
W: -7 (1)  
548 (35.4) 
M: -11 (1) 
W: -14 (1)* 
648 (46.8) 
M: -12 (1) 
W: -15 (1)* 
-blockers 252 (24.1) -16 (1) 408 (38.6) -10 (1) 383 (37.3) -11 (1) 
Diuretics 178 (19.3) -16 (1) 267 (31.6) -14 (1) 408 (49.1) -14 (1) 
CCB 189 (24.1) -11 (1) 284 (34.2) -11 (1) 291 (41.7) -6 (1)*† 
ARB 103 (17.9) 
M: -15 (1) 
W: -12 (1)  
179 (34.1) 
M: -14 (1) 
W: -14 (1) 
245 (48.0) 
M: -12 (1) 
W: -15 (1) 
Other 47 (27.8) -20 (1) 73 (36.4) -20 (1) 57 (35.8) -17 (1) 
DBP (mmHg)       
ACE Inhibitors 305 (17.8) 
M: -8 (1) 
W: -2 (1) 
548 (35.4) 
M: -7 (1) 
W: -4 (1) 
648 (46.8) 
M: -6 (1) 
W: -7 (1)*† 
-blockers 252 (24.1) -7 (1) 408 (38.6) -4 (1) 383 (37.3) -5 (1) 
Diuretics 178 (19.3) -4 (1) 267 (31.6) -5 (1) 408 (49.1) -6 (1) 
CCB 189 (24.1) -7 (1) 284 (34.2) -7 (1) 291 (41.7) -4 (1) 
ARB 103 (17.9) 
M: -4 (1) 
W: -4 (1) 
179 (34.1) 
M: -7 (1) 
W: -3 (1) 
245 (48.0) 
M: -8 (1) 
W: -7 (1) 
Other 47 (27.8) -10 (1) 73 (36.4) -10 (1) 57 (35.8) -8 (1) 
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Figure 3. Least squared adjusted means for A) Plasma glucose levels, B) TG levels, C) HDL 
levels (Men), D) HDL Levels (Women), E) WC (Men), and F) WC (Women) by 
antihypertensive drug type. All models adjusted for age, sex, BMI, education, health insurance, 
smoking, and physical activity levels. 
ACEI = ACE inhibitors; BB = -blockers; DI=diuretics; CCB = calcium channel blockers; 
ARB= angiotensin receptor blockers; TG=triglycerides; HDL= high-density lipoprotein; 
WC=waist circumference. 
a = significantly different from No BP Drug; b = significantly different from ACEI; c = 
significantly different from BB. 
Dashed line is the mean value for No BP Drug 
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APPENDIX A: BARORECEPTOR REFLEX MECHANISM 
 
  
CO= cardiac output 
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APPENDIX B: THE RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM 
(RAAS) 
 
 
 
ACE= angiotensin converting enzyme 
